---
title: "Enanta Pharmaceuticals Inc. Announces Date for Upcoming Annual Meeting of Stockholders"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273746401.md"
description: "Enanta Pharmaceuticals Inc. has announced that its 2026 Annual Meeting of Stockholders will take place virtually on March 11, 2026. Shareholders will vote on the election of two Class I directors for a term until the 2029 Annual Meeting and on an amendment to the 2019 Equity Incentive Plan to increase the number of shares available."
datetime: "2026-01-26T21:06:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273746401.md)
  - [en](https://longbridge.com/en/news/273746401.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273746401.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273746401.md) | [繁體中文](https://longbridge.com/zh-HK/news/273746401.md)


# Enanta Pharmaceuticals Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Enanta Pharmaceuticals Inc. has announced that its 2026 Annual Meeting of Stockholders will be held virtually on March 11, 2026. During the meeting, shareholders will vote on the election of two Class I directors to serve until the 2029 Annual Meeting of Stockholders and the approval of an amendment to Enanta’s 2019 Equity Incentive Plan to increase the number of shares available under the plan. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-022558), on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相关股票

- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Enanta Pharma (ENTA.US)](https://longbridge.com/zh-CN/quote/ENTA.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)

## 相关资讯与研究

- [Glenmark Pharmaceuticals Gets US FDA Nod for Fluticasone Propionate Inhalation Aerosol](https://longbridge.com/zh-CN/news/277723441.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-CN/news/278380208.md)
- [Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting](https://longbridge.com/zh-CN/news/278091205.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/zh-CN/news/278442392.md)
- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/zh-CN/news/277460502.md)